Drug Combination Details
| General Information of the Combination (ID: C34772) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | 1,25-dihydroxyvitamin D3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. | |||||
